**Core Concept**
Glanzmann thrombasthenia is a bleeding disorder characterized by the absence of functional platelet receptors, specifically the glycoprotein IIb/IIIa (GPIIb/IIIa) complex. This receptor complex is crucial for platelet aggregation and clot formation.

**Why the Correct Answer is Right**
The GPIIb/IIIa receptor complex plays a vital role in platelet aggregation by binding fibrinogen and von Willebrand factor. In Glanzmann thrombasthenia, the absence of this receptor complex leads to impaired platelet aggregation. To inhibit the same platelet receptor protein, a drug that acts as a competitive antagonist of GPIIb/IIIa receptor is used.

**Why Each Wrong Option is Incorrect**
**Option A:** Aspirin acts by inhibiting the enzyme cyclooxygenase (COX), which is involved in the production of thromboxane A2, a potent platelet aggregator. However, aspirin does not directly inhibit the GPIIb/IIIa receptor complex.

**Option B:** Clopidogrel acts by inhibiting the P2Y12 receptor, which is involved in the ADP-mediated platelet aggregation pathway. Although it affects platelet function, it does not directly inhibit the GPIIb/IIIa receptor complex.

**Option C:** Tirofiban is a non-peptide antagonist of the GPIIb/IIIa receptor complex, which is used to inhibit platelet aggregation in acute coronary syndrome. However, it is not the correct answer in this context.

**Clinical Pearl / High-Yield Fact**
The GPIIb/IIIa receptor complex is a high-yield topic in hematology, and it is essential to remember that Glanzmann thrombasthenia is due to the absence of this receptor complex. Tirofiban is a useful drug in the context of acute coronary syndrome, but it is not the correct answer in this question.

**Correct Answer:** C. Tirofiban is a non-peptide antagonist of the GPIIb/IIIa receptor complex, which is used to inhibit platelet aggregation in acute coronary syndrome.